SCIENTIFIC REPORTS

OPEN

A high risk of osteosarcoma in individuals who are homozygous for the p.D104N in endostatin

Received: 17 June 2015
Accepted: 14 October 2015
Published: 06 November 2015

Wen-Zhi Bi^{1,*}, Dian-Wei Li^{1,*}, Song Luo¹, Zhi-Gang Song², Yun Wang², Hua Jin³, Yan Wang¹, Qing Li⁴, Meng-Xia Li⁴, Dong Wang⁴, Bo Sun⁵, Meng Xu¹ & Cheng-Xiong Xu⁴

The D104N polymorphism (p.D104N) in endostatin has been previously identified in many types of cancer, and this polymorphism is believed to be a phenotypic modulator in some tumors. However, it is unknown whether endostatin p.D104N affects the risk and progression of osteosarcoma (OS). Here, we analyzed the p.D104N endostatin variant in 236 patients with OS and 418 healthy individuals. Similar frequencies of wild type and heterozygous p.104DN endostatin were observed in controls and OS patients. Interestingly, the frequency of the homozygous p.D104N (p.104NN) genotype was higher in OS patients group compared to control group, suggesting that individuals with p.104NN endostatin have a significantly increased risk for OS. In addition, OS patients with p.104NN endostatin had a shorter survival time and a higher rate of metastasis than OS patients with wild type endostatin. Animal experiments revealed that overexpression of p.104NN endostatin did not significantly inhibit OS lung metastasis. Interestingly, administration of endostatin dramatically inhibited OS lung metastasis in the p.104NN endostatin xenograft model. Together, these results suggest that p.104NN of endostatin is associated with the risk of OS and demonstrates predictive significance for clinical outcome in OS patients. In addition, endostatin therapy may be necessary for OS patients harboring p.104NN endostatin.

Osteosarcoma (OS) is the most common primary malignant tumor in children¹, and 30% of children diagnosed with OS will not survive for more than 5 years^{2,3}. Treatment of this disease often fails due to the development of metastasis⁴. However, the cellular mechanisms that underlie the development and metastasis of OS remain unclear.

Angiogenesis is a discrete event in carcinogenesis that is related to the aggressive potential of a tumor^{5,6}. Accumulating evidence suggests that tumor growth is associated with increased angiogenesis and that the formation of new blood vessels is a fundamental step in tumor development and expansion⁷. In addition, studies have suggested that increased angiogenic properties within a tumor are associated with poorer clinical outcomes⁸. As is the case for numerous types of cancer, OS is dependent on angiogenesis⁹. Therefore, anti-angiogenic therapy has become a vital part of the arsenal against OS^{10,11}.

Endostatin is a 183-amino-acid proteolytic fragment that is produced by the cleavage of the C-terminal non-collagenous domain (NC1) of human type XVIII collagen; endostatin is an efficient anti-angiogenic molecule¹². As an angiogenic inhibitor, endostatin prevents tumor growth and expansion by controlling

¹Departments of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.

²Department of Pathology, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.

³Department of Molecular Pharmacology and Physiology, University of South Florida Health Sciences Center, Tampa, FL 33647, USA. ⁴Cancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing 400042, China. ⁵State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to M.X. (email: xumeng301@gmail.com) or C.X.X. (email: xuchengxiong@hanmail.net)

Genotypes	Controls number (%)	Patients Number (%)
p.104NN	3 (0.7)	8 (3.4)
p.104DN	39 (9.3)	23 (9.7)
Wild	376 (90.0)	205 (86.9)

Table 1. Endostatin genotype distribution among osteosarcoma patients and controls. Wild, no polymorphism; p.104DN, heterozygous polymorphism; p.104NN, homozygous polymorphism.

the formation of new blood vessels. *In vitro* and *in vivo* studies have shown that endostatin treatment can increase apoptosis and decrease microvessel density and metastasis in many tumors, including OS^{10,11,13}. A single nucleotide polymorphism, c.4309G > A (p.D104N), has been identified in the endostatin domain of COL18A1; this polymorphism affects a site that is conserved in humans and mice^{14,15}. A polymorphism can influence gene function¹⁶ and recent studies show that some polymorphism is strongly associated with the clinical significance in cancers^{17,18}. So, the frequencies of endostatin p.D104N variant has been previously evaluated in healthy individuals and various diseases including cancers^{19,20}. Iughetti *et al.* reported that the presence of the p.D104N variant results in a 2.5-fold increased risk of prostate cancer²¹. In addition, studies in breast cancer showed that endostatin p.D104N is associated with invasive breast cancer¹⁵, and patients carrying this polymorphism exhibited shorter progression-free survival and overall survival compared to those with wild type endostatin²². However, it is not known whether this polymorphism in endostatin affects the risk and progression of OS.

Therefore, we aimed to determine the frequency of the wild type, heterozygous p.D104N (p.104DN), and homozygous p.D104N (p.104NN) endostatin genotypes in patients with OS and to determine the influence of this polymorphism on OS risk, biological features and clinical outcomes.

Results

Distribution of the p.D104N endostatin variant in OS patients. First, we analyzed the distribution of the p.D104N endostatin variants in the healthy control and OS patient groups (Table 1). Of the 236 OS patients, 205 were normal homozygous (wild type) and 23 were heterozygous for the p.D104N. Of the 418 healthy individuals, 376 harbored the wild genotype of endostatin, 39 had the p.104DN genotype and 3 had the p.104NN genotype. We observed no significant differences in the frequencies of the wild type and p.104DN genotypes between the OS patient group and the healthy control group. However, we observed a higher frequency of individuals who were homozygous for p.D104N in the OS patient group (3.4%) than in the control group (0.7%) (Table 1).

OS patients with the p.104NN genotype of endostatin have worse clinical outcomes. Next, we analyzed the association between p.D104N endostatin variants and clinical outcomes among OS patients. There was no difference in the clinical and laboratory features of OS patients with different p.D104N endostatin variants (Table 2). However, the OS patient group with the p.104NN genotype had a lower 5-year survival rate compared to the OS patient group with wild type or p.104DN endostatin (Fig. 1a). In addition, the OS patient group with the p.104NN genotype had a higher metastatic rate compared to the OS patient group with the wild type endostatin (Fig. 1b). In addition, we used an OS xenograft model to confirm the effect of p.104NN endostatin on OS lung metastasis. Similar to the clinical data, the animal experimental data revealed that overexpressing p.104NN endostatin did not significantly inhibit OS lung metastasis (Fig. 2a); wild type endostatin inhibits OS tumor growth²³, and tumor size may be related to metastasis²⁴. Therefore, in a subsequent experiment, we removed the primary tumors from animals with similarly sized tumors ($532 \pm 52 \text{ mm}^3$) and counted the macroscopic pulmonary metastatic foci 2 weeks after surgery. Similar to the results of the previous animal study, p.104NN endostatin did not inhibit OS lung metastasis (Fig. 2b). Interestingly, treating the OS p.104NN endostatin xenograft model with endostatin significantly inhibited OS lung metastasis compared to control (Fig. 2c).

The p.104NN endostatin genotype does not inhibit endostatin expression. Next, we investigated the effects of the p.104NN genotype on endostatin expression because a single polymorphism can influence gene expression²⁵. In accordance with previous reports, the median serum endostatin value in the 236 OS patients (272.4 ng/ml) was higher than that in the 100 healthy individuals (95.1 ng/ml) (Fig. 3a). However, there was no difference in the median serum endostatin concentration between the 8 carriers of the wild genotype (95.7 ng/ml) and the 92 carriers of the p.104DN allele (94.5 ng/ml) among the healthy control individuals ($p = 0.92$; Fig. 3b). Similarly, there were no differences in the median serum endostatin concentration among the 8 carriers of p.104NN endostatin (272.9 ng/ml), the 23 carriers of p.104DN endostatin (278.7 ng/ml), and the 205 carriers of wild type endostatin (265.6 ng/ml; $p = 0.79$) within the OS patient group (Fig. 3c). Furthermore, consistent with these data, we did not

	Patients number	Wild+p.104DN(%)	p.104NN(%)	p-value
Sex				1.00
Male	139	134(96.4)	5(3.6)	
Female	97	94(96.9)	3(3.1)	
Age				1.00
20≤	162	157(96.9)	5(3.1)	
>20	74	71(95.9)	3(4.1)	
Histologic subtype				0.65
Osteoblastic	146	142(97.3)	4(2.7)	
Chondroblastic	35	33(94.3)	2(5.7)	
Fibroblastic	21	20(95.2)	1(4.8)	
Other	34	33(97.1)	1(2.9)	
Grade				1.00
III	61	59(96.7)	2(3.3)	
IV	175	169(96.6)	6(3.4)	
Enneking stage				0.72
2A	59	56(94.9)	3(5.1)	
2B	177	172(97.2)	5(2.8)	

Table 2. Endostatin genotype distributions in osteosarcoma patients stratified by clinical and laboratory variables. Wild, no polymorphism; p.104DN, heterozygous polymorphism; p.104NN, homozygous polymorphism.

Figure 1. Homozygous D104N polymorphisms (p.104NN) in endostatin are associated with reduced survival and a high metastatic rate. (a) The survival rate was determined using the Kaplan-Meier method. The survival rate was significantly lower in osteosarcoma (OS) patients with p.104NN endostatin compared to OS patients who were heterozygous for the D104N polymorphism (p.104DN) or who harbored wild type endostatin. (b) The OS metastasis rate was higher in OS patients with p.104NN endostatin compared to OS patients with p.104DN or wild type endostatin.

observe any differences in endostatin expression in the tumor tissues from the OS patients with different p.D104N genotypes (Fig. 3d).

The p.104NN genotype does not affect the anti-angiogenesis function of endostatin in OS. Endostatin inhibits tumor metastasis partly by inhibiting angiogenesis²⁶, and p.D104N potentially impairs endostatin function²¹. Thus, we examined the effects of the p.104NN genotype on the anti-angiogenic activity of endostatin. First, we measured the microvessel density in tissue samples from OS patients with different endostatin p.D104N variants. Angiogenesis was slightly increased in OS patients with the p.104NN genotype, but the differences among these OS patients were not significant (Fig. 4a). In agreement with the clinical data, the animal experimental results showed that p.104NN did not significantly affect the anti-angiogenic activity of endostatin (Fig. 4b). Together, these data indicated that p.104NN does not affect the anti-angiogenesis function of endostatin.

Figure 2. Overexpression of homozygous D104N (p.104NN) endostatin does not significantly inhibit osteosarcoma (OS) lung metastasis.

(a) OS pulmonary metastasis was significantly inhibited by wild type endostatin but not by p.104NN endostatin ($n = 8$ mice). Mice were inoculated subcutaneously with LM8 cells that had been transfected with the indicated plasmid. Two weeks after inoculation, the mice were anesthetized, and the primary tumors were removed surgically. The lungs were removed 2 weeks after surgery, and the macroscopic pulmonary metastasis foci were counted. (b) Mice were inoculated subcutaneously with LM8 cells that had been transfected with the indicated plasmid. After the tumors reached $532 \text{ mm}^3 (\pm 52)$, the mice were anesthetized, and the primary tumors were removed surgically. The lungs were removed 2 weeks after surgery, and the macroscopic pulmonary metastasis foci were counted. (c) Treatment with endostatin significantly inhibited OS lung metastasis in the p.104NN endostatin expressing LM8 xenograft model. Mice were inoculated subcutaneously with LM8 cells that had been transfected with the p.104NN endostatin plasmid. Two weeks after inoculation, the mice were anesthetized, and the primary tumors were removed surgically. Then, the mice were treated with endostatin (5 mg/kg, every 2 days) or PBS. The lungs were removed 2 weeks after surgery, and the macroscopic pulmonary metastasis foci were counted.

Discussion

The D104N polymorphism in endostatin has been previously reported in many types of cancer, and this polymorphism is believed to be a phenotypic modulator in some benign and malignant tumors²¹. However, these data are controversial, and different results have been reported in different cancer types. For example, studies have shown that the heterozygous p.D104N of endostatin is associated with an increased risk of prostate cancer²⁷ and invasive breast cancer¹⁵ and with worse clinical outcomes for

Figure 3. The D104N polymorphism (p.D104N) does not affect endostatin expression. (a) Serum endostatin levels were significantly higher in osteosarcoma (OS) patients (n = 236) compared to healthy individuals (n = 100). (b) The p.D104N does not affect serum endostatin levels in healthy individuals. (c) The p.D104N does not affect serum endostatin levels in OS patients. (d) The p.D104N does not affect endostatin expression in OS tissue. Immunohistochemistry assays were performed on primary tumor tissues from OS patients. Dark brown color indicates endostatin expression. Each bar represents the mean $\pm$ SD. Wild, wild type endostatin; p.104DN, heterozygous D104N polymorphism; p.104NN, homozygous D104N polymorphism.

Figure 4. The D104N polymorphism in endostatin does not significantly affect angiogenesis in patients with osteosarcoma. (a) Microvessels were detected using CD31 immunofluorescence in primary tumor samples from OS patients. (b) Microvessels were detected in primary tumors from the LM8 xenograft model. Each bar represents the mean $\pm$ SD. Wild, wild type endostatin; p.104DN, heterozygous D104N polymorphism; p.104NN, homozygous of D104N polymorphism.

gastric cancer²², whereas no associations were observed between the heterozygous p.D104N genotype and the risk of multiple myeloma²⁸ and lung cancer²⁹. These discrepant results may be due to the heterogeneity of different cancers. This is the first study to report the frequency of the p.D104N polymorphism

in endostatin in OS patients and to ascertain whether p.D104N alters the risk and clinical manifestations of OS.

In the present study, we observed no differences in the frequencies of the wild type and p.104DN genotypes of endostatin between healthy control individuals and OS patients. Interestingly, we found that individuals with p.104NN had a significantly greater risk of disease occurrence. These data suggest that p.104NN endostatin may be associated with OS susceptibility. In addition, our data revealed that patients with p.104NN endostatin have a shorter survival time and a higher rate of metastasis, suggesting that the p.104NN genotype of endostatin is associated with poor clinical outcome. Our animal experimental data demonstrated that overexpressing p.104NN endostatin does not significantly inhibit OS lung metastasis. Together, these data suggest that p.104NN endostatin may be a useful candidate marker for predicting OS disease progression.

Interestingly, the animal experiments showed that endostatin treatment can significantly inhibit OS lung metastasis in the p.104NN endostatin OS xenograft model, suggesting that endostatin therapy may be useful for preventing OS lung metastasis in OS patients with p.104NN endostatin. However, we did not observe a significant association between the different p.D104N endostatin variants and tumor aggressiveness in the OS patients. This result may be due to the inclusion of relatively few individuals with the p.104NN variant in this study, suggesting future study is needed in the larger OS patient population. A similar result has been observed for other tumor types. Lourenco *et al.* first reported that the p.104NN endostatin genotype is present in patients with sporadic breast cancer (SBC) but absent in control individuals, suggesting that the p.104NN genotype of endostatin is associated with SBC susceptibility. They also observed no association between the p.104NN endostatin genotype and tumor aggressiveness³⁰, which is similar to the results reported here.

According to previous reports, polymorphisms can alter gene expression and function²⁷. So, we hypothesized that the decreased anti-tumor effect of p.104NN endostatin may be due downregulated expression or loss of function of endostatin. However, our data showed that p.104NN does not affect endostatin expression. Our results are supported by previously published studies¹⁵. These data suggested that the effect of p.104NN on the anti-tumor activity of endostatin was not due to the inhibition of endostatin expression. Therefore, we examined the effects of p.104NN on the anti-angiogenic activity of endostatin. Endostatin is an anti-angiogenic factor, and studies have shown that the antitumor effects of endostatin are mediated partly by inhibiting angiogenesis³¹. Unfortunately, angiogenesis was slightly increased in patients with p.104NN endostatin compared to patients with wild type endostatin. Similar results were observed in the animal experiment, suggesting that the diminished anti-tumor effects of p.104NN endostatin are not due to modulation of anti-angiogenic activity. Thus, the mechanisms by which p.104NN weakens the anti-tumor effects of endostatin are unclear, and future studies are needed.

In summary, our study is the first to report preliminary evidence that the p.104NN genotype of endostatin is associated with OS susceptibility and poor clinical outcome and that it has predictive significance for the clinical outcome of OS patients. In addition, endostatin therapy may be necessary for OS patients with p.104NN endostatin.

Methods

Materials. EDTA-containing vacutainer tubes were obtained from BD vacutainer (Franklin Lake, NJ, USA). Genomic DNA isolation kits were purchased from Qiagen (Germantown, MD, USA). Endostatin human ELISA kits and primary antibodies against CD31 and endostatin were obtained from Abcam (Cambridge, MA, USA). Permount, Hematoxylin and secondary antibodies conjugated to HRP or FITC green were obtained from Sigma (St. Louis, MO, USA). DAB peroxidase substrate kits and DAPI-containing mounting media for immunofluorescence were purchased from Vector Labs (Burlingame, CA, USA). Endostatin was obtained from Shandong Xiangsheng Maidejin Biological Pharmaceutical Co.

Human specimens. All the experimental methods were carried out in accordance with the approved guidelines. Blood and tumor samples were obtained from 236 OS patients primary tumors during diagnostic surgical biopsies (no metastasis). Blood samples were also obtained from 418 healthy individuals. The characteristics of the OS patients and the controls are summarized in Table 3. This research was approved by the Research Ethics Board of the General Hospital of the People's Liberation Army. After describing the research study and the related procedures, written informed consent was obtained from the adult patients or from legally authorized representatives if the patients were minors.

Genomic DNA amplification and genotyping. Genomic DNA was isolated from the blood samples (healthy individuals) and the diagnostic biopsy specimens (OS patients) using a Qiagen genomic DNA isolation kit according to the manufacturer's instructions. Genotyping was performed as described by Balasubramanian *et al.* using the same primers¹⁵.

Immunostaining assay. The tumor tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned at a thickness of 4 μ m. The tissue sections were deparaffinized in xylene and then rehydrated via an alcohol gradient. Antigen retrieval was then performed using 10 mM citrate buffer (pH 6.0). For immunofluorescence (IF), the tissue sections were directly incubated in a solution of 3% bovine serum albumin (BSA) in PBS for 1 h at room temperature (RT). For immunohistochemistry

	Patients number	Healthy individuals number	p-value
Sex			0.33
Male	139 (58.9)	229(54.8)	
Female	97(41.1)	189(45.2)	
Histologic subtype			
Osteoblastic	146(61.9)	NA	
Chondroblastic	35(14.8)	NA	
Fibroblastic	21(8.9)	NA	
Other	34(14.4)	NA	
Grade			
III	61(25.8)	NA	
IV	175(74.2)	NA	
Enneking stage			
2A	59(25.0)	NA	
2B	177(75.0)	NA	

Table 3. Characteristics of osteosarcoma patients and controls.

(IHC), tissue sections were incubated in 3% hydrogen peroxide in methanol for 10 min and then washed with PBS. Then, the tissue sections were incubated in a 3% BSA solution. The slides were then incubated with a primary antibody overnight at 4°C. The following day, the tissue sections were washed and incubated with the secondary HRP-conjugated (for IHC) or FITC-conjugated (for IF, in the dark) antibodies at RT. After a 1-h incubation, the slides were washed with PBS in the dark. For IF, a cover slip was affixed using mounting medium with DAPI. For IHC, the substrate color was developed using a DAB peroxidase substrate kit, and the sections were counterstained with hematoxylin. Next, cover slips were mounted using Permount. The number of CD31-positive vessels was counted in four randomly selected 1 mm² areas in a high power field (HPF), and the average number was calculated. To quantify the total surface area of the vasculature, the total perimeter of the vessels was measured in five randomly selected 0.25 mm² areas using an image analyzer. Endostatin-positive staining was determined by counting 5 randomly chosen fields per section, and the percentage of DAB-positive cells per 100 cells was determined at ×400.

ELISA assays. Blood samples were collected in EDTA-containing tubes, and the serum samples were separated and stored at −70°C for future use. Serum endostatin levels were measured using a commercially available ELISA according to the manufacturer's instructions. All of the measurements were performed in duplicate to ensure the accuracy of the collected data.

Animal study. An animal study was performed as described by Kaya *et al.*²³. Briefly, female BALB/c nu/nu mice (8 mice/group) were inoculated subcutaneously with LM8 cells that had been transfected with the indicated endostatin variant (1×10^6 cells/mouse). One week after inoculation, blood samples were collected from the tail vein and analyzed for endostatin. At the indicated times after inoculation, the mice were anesthetized, and the primary tumors were removed surgically. The lungs were removed 2 weeks after surgery, and the macroscopic pulmonary metastatic foci were counted.

For the endostatin therapy experiment, the mice were inoculated subcutaneously with p.104NN endostatin-overexpressing LM8 cells (1×10^6 cells/mouse). Two weeks after inoculation, the mice were anesthetized, and the primary tumors were removed surgically. After the primary tumor was removed, endostatin was administered to the treatment group by intraperitoneal injection (5 mg/kg, every 2 days). The control group received physiological saline. The lungs were removed 2 weeks after endostatin treatment, and the macroscopic pulmonary metastatic foci were counted. The experimental animal protocol was approved by the institutional review board of the General Hospital of the People's Liberation Army and was performed in accordance with accepted guidelines for animal research.

Statistical analyses. Hardy-Weinberg equilibrium was evaluated using the X^2 statistic for the goodness-to-fit (using one degree of freedom). The statistical significance of the differences between groups was calculated using the X^2 test or Fisher's exact test. All the analyses were performed using the SAS statistical package for Windows, version 8.1 (SAS Institute Incorporation, USA).

References

- Messerschmitt, P. J., Garcia, R. M., Abdul-Karim, F. W., Greenfield, E. M. & Getty, P. J. Osteosarcoma. *J Am Acad Orthop Surg* **17**, 515–527 (2009).
- Broadhead, M. L., Clark, J. C., Myers, D. E., Dass, C. R. & Choong, P. F. The molecular pathogenesis of osteosarcoma: a review. *Sarcoma* **2011**, 959248 (2011).
- Marulanda, G. A., Henderson, E. R., Johnson, D. A., Letson, G. D. & Cheong, D. Orthopedic surgery options for the treatment of primary osteosarcoma. *Cancer Control* **15**, 13–20 (2008).
- Huang, J. *et al.* HMGB1 promotes drug resistance in osteosarcoma. *Cancer Res* **72**, 230–238 (2012).
- Nakamura, Y. *et al.* Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. *Breast Cancer Res Treat* **91**, 125–132 (2005).
- Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* **86**, 353–364 (1996).
- Mariani, B. M. *et al.* Genotype analysis of the human endostatin variant p.D104N in benign and malignant adrenocortical tumors. *Clinics (Sao Paulo)* **67**, 95–98 (2012).
- Yu, X. W. *et al.* Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. *Tumour Biol* **35**, 155–60 (2013).
- Kim, H. S., Lim, S. J. & Park, Y. K. Anti-angiogenic factor endostatin in osteosarcoma. *APMIS* **117**, 716–723 (2009).
- Xu, M. *et al.* Effects of endostar combined multidrug chemotherapy in osteosarcoma. *Bone* **57**, 111–115 (2013).
- Fu, X. H. *et al.* Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. *Cancer Lett* **312**, 109–116 (2011).
- O'Reilly, M. S. *et al.* Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* **88**, 277–285 (1997).
- Jiang, W. G. *et al.* Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis. *BMC Cancer* **13**, 479 (2013).
- Visakorpi, T. Molecular genetics of prostate cancer. *Annales chirurgiae et gynaecologiae* **88**, 11–16 (1999).
- Balasubramanian, S. P. *et al.* Endostatin gene variation and protein levels in breast cancer susceptibility and severity. *BMC Cancer* **7**, 107 (2007).
- Kuramoto, T., Nakanishi, S. & Serikawa, T. Functional polymorphisms in inbred rat strains and their allele frequencies in commercially available outbred stocks. *Physiol Genomics* **33**, 205–211 (2008).
- Iguchi, T. *et al.* Association of MnSOD AA Genotype with the Progression of Prostate Cancer. *PloS one* **10**, e0131325 (2015).
- Schuster, D. P. *et al.* Translational and Experimental Clinical Research (eds Schuster, D.P. & Powers, W.J.) Ch.32, 343–355 (Lippincott Williams & Wilkins, 2005).
- Mucci, L. A. *et al.* Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. *Int J Cancer* **125**, 1143–1146 (2009).
- Macpherson, G. R. *et al.* Genotyping and functional analysis of the D104N variant of human endostatin. *Cancer Biol Ther* **3**, 1298–1303 (2004).
- Iughetti, P. *et al.* A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. *Cancer Res* **61**, 7375–7378 (2001).
- Dan, S., Bai, L., Li-Jie, W., Ting, Z. & Zhi-Yuan, M. Pharmacogenetic angiogenesis profiling for first-line chemotherapy in patients with advanced gastric cancer. *Cancer Invest* **31**, 390–396 (2013).
- Kaya, M., Wada, T., Nagoya, S. & Yamashita, T. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. *J Orthop Sci* **12**, 562–567 (2007).
- Minn, A. J. *et al.* Lung metastasis genes couple breast tumor size and metastatic spread. *Proc Natl Acad Sci USA* **104**, 6740–6745 (2007).
- Boffa, M. B. *et al.* Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. *Blood* **111**, 183–189 (2008).
- Bleziinger, P. *et al.* Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. *Nature Biotech* **17**, 343–348 (1999).
- Iughetti, P. *et al.* A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. *Cancer Res* **61**, 7375–7378 (2001).
- Ortega, M. M., Nascimento, H., Costa, F. F., Teori, M. T. & Lima, C. S. A polymorphism in the angiogenesis inhibitor, endostatin, in multiple myeloma. *Leuk Res* **27**, 93–94 (2003).
- Zamboni, L. *et al.* A polymorphism in the angiogenesis inhibitor, endostatin, in lung cancer susceptibility. *Lung Cancer* **59**, 276–278 (2008).
- Lourenco, G. J. *et al.* A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene. *Breast Cancer Res Treat* **100**, 335–338 (2006).
- Wickstrom, S. A., Alitalo, K. & Keski-Oja, J. Endostatin signaling and regulation of endothelial cell-matrix interactions. *Adv Cancer Res* **94**, 197–229 (2005).

Acknowledgements

This work was supported by the China International Medical Foundation (CIMF-F-H001-240), and the National Natural Science Foundation of China (NSFC-81172553).

Author Contributions

C.X.X., M.X. and D.W.L. contributed to the conception and design of the study; W.Z.B., M.X., D.W.L., Y.W. and S.L. collected and provided the human samples; W.Z.B., H.J., L.M.X., B.S. and Y.W. performed laboratory experiments; Z.G.S., C.L., Q.L. and D.W. analyzed clinical data; C.X.X., H.J. and M.X. discussed the results and wrote the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Bi, W.-Z. *et al.* A high risk of osteosarcoma in individuals who are homozygous for the p.D104N in endostatin. *Sci. Rep.* **5**, 16392; doi: 10.1038/srep16392 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>